Company intelligence / Profile preview

Aerpio Therapeutics

Cincinnati, Ohio, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

AKB‐9778, a first-in-class Tie2 activator, completed a Phase IIb trial in nonproliferative diabetic retinopathy. Results showed reduction in intraocular pressure and improved kidney function over 48 weeks. In combination with Lucentis for DME, it achieved greater retinal drying than ranibizumab alone. Some positive secondary endpoints were observed.[10][5]

Therapeutic areas: Ophthalmology
Modalities: Small moleculesMonoclonal antibodies[2][3]
Industry: Biotech

Partnerships

Novartis BioVentures and other VCs as investors; no major pharma co-development partnerships disclosed pre-merger.[8]

Beyond the preview

Go deeper on Aerpio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerpio Therapeutics.